ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

IVVD Invivyd Inc

1.84
0.03 (1.66%)
01 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Invivyd Inc NASDAQ:IVVD NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.03 1.66% 1.84 1.62 1.93 1.91 1.80 1.80 679,440 01:00:00

Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights

02/05/2024 10:13pm

GlobeNewswire Inc.


Invivyd (NASDAQ:IVVD)
Historical Stock Chart


From May 2024 to Jun 2024

Click Here for more Invivyd Charts.

Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, May 9, 2024, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2024, and recent business highlights.

Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.

About Invivyd

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company’s proprietary INVYMAB™ platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb in a planned series of innovative antibody candidates. Visit https://invivyd.com/ to learn more.

Contacts:

Media Relations(781) 208-1747media@invivyd.com

Investor Relations(781) 208-1747investors@invivyd.com

1 Year Invivyd Chart

1 Year Invivyd Chart

1 Month Invivyd Chart

1 Month Invivyd Chart

Your Recent History

Delayed Upgrade Clock